AmantadineLC: Amantadine Therapy for Cognitive Impairment in Long COVID

Sponsor

Ohio State University (Other)

Overall Status

Not yet recruiting

CT.gov ID

NCT06055244

Collaborator

(none)

Enrollment

Location

Arms

Anticipated Duration (Months)

3.2

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This study will look at the effects of amantadine on cognitive function in persons with Long COVID. It will also collect specimens to study possible causes of cognitive symptoms in Long COVID, and whether any lab tests can predict who will respond better to amantadine.

Condition or Disease	Intervention/Treatment	Phase
Long COVID Post-COVID19 Condition Post-Acute COVID19 Syndrome	Drug: Amantadine	Phase 1

Detailed Description

This study will enroll 60 subjects with Long COVID and cognitive symptoms such as problems with memory, concentration, speech and attention, and "brain fog." Subjects will be assigned randomly to two groups. One group will be treated with amantadine, the other group will receive placebo. The study will last 4 months. During that time, subjects will be assessed at regular intervals with symptom questionnaires, cognitive tests, and lab measurements.

Study Design

Study Type:

Interventional

Anticipated Enrollment :

60 participants

Allocation:

Randomized

Intervention Model:

Single Group Assignment

Intervention Model Description:

Pilot randomized clinical trialPilot randomized clinical trial

Masking:

Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

Primary Purpose:

Treatment

Official Title:

Amantadine Therapy for Cognitive Impairment Related to Post-COVID Condition

Anticipated Study Start Date :

Oct 15, 2023

Anticipated Primary Completion Date :

Apr 15, 2025

Anticipated Study Completion Date :

May 15, 2025

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Amantadine Subjects will be treated with amantadine.	Drug: Amantadine Subjects will be give amantadine 100 mg twice daily.
Placebo Comparator: Placebo Subjected received placebo identical to amantadine in appearance.	Drug: Amantadine Subjects will be give amantadine 100 mg twice daily.

Arm

Intervention/Treatment

Experimental: Amantadine

Subjects will be treated with amantadine.

Drug: Amantadine

Subjects will be give amantadine 100 mg twice daily.

Placebo Comparator: Placebo

Subjected received placebo identical to amantadine in appearance.

Drug: Amantadine

Subjects will be give amantadine 100 mg twice daily.

Outcome Measures

Primary Outcome Measures

Improvement in cognitive symptoms [4 months]
Improvement in scores on self-assessment of overall cognitive functioning
Improvement on objective cognitive testing [4 months]
Subjects will be administered battery of cognitive tests to determine if there is a change in objective cognitive function

Secondary Outcome Measures

Mood symptoms [4 months]
Subjects will be administered anxiety and depression questionnaires to determine if there is improvement in mood symptoms.
Medication tolerability [4 months]
Subjects will complete a questionnaire addressing tolerability of amantadine and side effects experienced

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

18 years of age and above at the signing of informed consent
Had a positive laboratory or home test for COVID19 within one year prior to signing of informed consent, with subsequent symptoms meeting criteria for PASC.
Subjective Cognitive impairment associated with PASC
Cognitive symptoms will be formally assessed at a pre-enrollment visit using the PROMIS Cognitive Function Questionnaire (CGQ) and the PROMIS Cognitive Abilities subset (CAS), which are validated patient-reported measures of subjective cognitive functioning. Potential participants must have a cumulative score less than 60 (indicating at least mild subjective cognitive dysfunction) to be eligible.
Is willing and able to comply with study visits and study-related procedures/assessments.
Is able to provide informed consent to participate in the study 5.
Is not currently taking a medication with adverse interactions with amantadine. (Table

If the participant is of child bearing potential, , is not pregnant at enrollment based on negative urine pregnancy test.
If the participant is of child-bearing potential, is consistently using one or more forms of prescribed birth control, such as an oral contraceptive, intrauterine device or a long-acting reversible contraceptive.
Is not breastfeeding.
Is willing to abstain from alcohol use for the duration of the study.
Endorses self-reported cognitive impairment on the PROMIS CF[40].
Does not have any other contraindications to amantadine use as noted in section 6 below or as identified by the study clinician investigators.

Exclusion Criteria:

At risk for complications of study drug with conditions such as:

Lifetime history of compulsive or impulsive behavior: Compulsive gambling, hypersexuality, binge eating; suicidality.
Underweight, malnourished at time of enrollment.
History of restrictive eating disorder within 3 months prior to consent.
Lifetime history of heart failure or diagnosed cardiac arrhythmia.
Untreated angle closure glaucoma at time of enrollment.
Lifetime history of psychosis or psychotic disorder.
Lifetime history of seizure disorder.
Known allergy to amantadine.
History of binge drinking, heavy alcohol use, or alcohol use disorder as defined by the National Institute on Alcohol Abuse and Alcoholism (NIAAA)[54] and the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5)[55].
Use of kava-kava within 3 months prior to consent.
Breastfeeding at screening or expected to be breastfeeding during study period.
Pregnant at time of screening or expecting to become pregnant during the study period.

Is taking a medication that adversely interacts with amantadine (see Table 2)
Has any physical examination findings, and/or history of any illness, concomitant medications or recent live vaccines that, in the opinion of the study investigator, might confound the results of the study or pose an additional risk to the subject by their participation in the study.
Prior diagnosis of dementia, neurodegenerative disorder, multiple sclerosis or other autoimmune neurologic disorder, or cognitive impairment.
Enrolled in any other research study involving intervention for PASC.
If the individual is of child-bearing potential, is not consistently using one or more forms of prescribed birth control.
Is not willing to abstain from alcohol for the duration of the study.
Is not willing and able to adhere to study visits and study-related procedures/assessments.
Is not able to provide informed consent to participate in the study.